(MENAFN- GlobeNewsWire - Nasdaq) Transformative Growth Ahead for Immunotherapy Drugs as Precision Medicine, AI, and Biologics Propel Market Innovation and Expansion

Dublin, Dec. 05, 2025 (GLOBE NEWSWIRE) -- The "Immunotherapy Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ResearchAndMarkets's offering.
The Global Immunotherapy Drugs Market was valued at USD 201.3 billion in 2024 and is estimated to grow at a CAGR of 10.2% to reach USD 526.5 billion by 2034.
The market expansion is influenced by the rising prevalence of chronic illnesses, including cancer, autoimmune, and infectious diseases, coupled with continuous innovation in antibody engineering. Advanced therapeutic technologies such as CAR-T cell therapy, bispecific antibodies, and immune checkpoint inhibitors are transforming treatment paradigms, offering improved efficacy and safety over conventional therapies.

Artificial intelligence is accelerating drug discovery, while biomarker-driven clinical development is enhancing patient selection and treatment success rates. The ongoing shift toward precision and personalized medicine continues to strengthen market growth, as therapies designed around genetic and molecular profiles gain global acceptance.

Emerging approaches such as neoantigen-based vaccines and biomarker-guided regimens are advancing rapidly, supported by progress in genomics, proteomics, and diagnostic tools that improve monitoring and outcomes. Immunotherapy drugs are designed to modify or regulate immune responses, helping the body combat various diseases through either immune activation or suppression mechanisms using biologically engineered substances such as antibodies or proteins.
The monoclonal antibodies segment accounted for 63.3% share in 2024 and is expected to reach USD 340 billion by 2034, growing at a CAGR of 10.4%. The rising incidence of chronic conditions continues to drive strong demand for targeted biologics. Monoclonal antibodies have become a cornerstone of treatment due to their superior selectivity and reduced side effects compared to traditional pharmaceuticals. Their ability to target specific molecular pathways has made them indispensable in modern medical therapies and positioned them as one of the most valuable components of immunotherapy development worldwide.
The cancer segment generated USD 130.4 billion in 2024, maintaining its position as the leading therapeutic area within the global immunotherapy drugs market. The surge in global cancer cases and the ongoing evolution of advanced biological therapies are central to market expansion. Innovative treatments, including immune checkpoint modulators, monoclonal antibodies, and next-generation cell therapies, have redefined oncology care by improving patient survival and response rates. The autoimmune disease segment is also recording rapid growth as the focus shifts from generalized immune suppression to precision-targeted biologic therapies, resulting in better disease management and fewer adverse effects.
U.S. Immunotherapy Drugs Market reached USD 83.1 billion in 2024, reinforcing its global leadership position in research, development, and clinical innovation. The country's ecosystem of biotechnology startups, pharmaceutical giants, and strong federal support enables rapid commercialization of novel immunotherapies. Ongoing investments by companies such as Amgen, Pfizer, and Johnson & Johnson are expanding the pipeline of next-generation biologics and cellular therapies, with numerous investigational new drug approvals highlighting the nation's commitment to accelerating immunotherapy advancements.
Major participants in the Global Immunotherapy Drugs Market include Bristol Myers Squibb, AstraZeneca, Gilead Sciences, F. Hoffmann La Roche, Johnson & Johnson, Novartis, GlaxoSmithKline, Sanofi, Merck & Co., Moderna, Pfizer, Amgen, Kite Pharma, Adaptimmune Therapeutics, and Bluebird Bio.

Key companies in the Global Immunotherapy Drugs Market are employing diverse strategies to enhance their global presence and strengthen competitiveness. They are expanding R&D programs targeting novel immune pathways and investing in next-generation biologics such as bispecific antibodies and CAR-T platforms. Strategic alliances, mergers, and acquisitions are enabling them to access cutting-edge technologies and accelerate clinical development timelines. Firms are also focusing on regional expansion, particularly in emerging economies, to increase access to advanced treatments.

Key Attributes:

Report Attribute	Details
No. of Pages	135
Forecast Period	2024 - 2034
Estimated Market Value (USD) in 2024	$201.3 Billion
Forecasted Market Value (USD) by 2034	$526.5 Billion
Compound Annual Growth Rate	10.2%
Regions Covered	Global

Key Topics Covered:
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
2.1 Industry 360-degree synopsis
2.2 Key market trends
2.2.1 Regional trends
2.2.2 Drug type trends
2.2.3 Application trends
2.2.4 Route of administration trends
2.2.5 End Use trends
2.3 CXO perspectives: Strategic imperatives
2.3.1 Key decision points for industry executives
2.3.2 Critical success factors for market players
2.4 Future outlook and strategic recommendations
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.1.1 Supplier landscape
3.1.2 Value addition at each stage
3.1.3 Factors affecting the value chain
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of chronic diseases
3.2.1.2 Technological advancement in antibody engineering
3.2.1.3 Growing demand for personalized and targeted therapies
3.2.1.4 Expansion into non-oncology applications
3.2.2 Industry pitfalls and challenges
3.2.2.1 High cost and limited accessibility
3.2.2.2 Variable patient response and resistance
3.2.3 Market opportunities
3.2.3.1 Decentralized manufacturing and regional hubs
3.2.3.2 Personalized neoantigen vaccines
3.3 Growth potential analysis
3.4 Regulatory landscape
3.4.1 North America
3.4.2 Europe
3.4.3 Asia-Pacific
3.5 Technology landscape
3.5.1 Current technological trends
3.5.2 Emerging technologies
3.6 Future market trends
3.7 Pricing analysis
3.8 Clinical trial analysis
3.9 Porter's analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
4.1 Introduction
4.2 Company market share analysis
4.2.1 Global
4.2.2 North America
4.2.3 Europe
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Key developments
4.6.1 Merger and acquisition
4.6.2 Partnership and collaboration
4.6.3 New product launches
4.6.4 Expansion plans
Chapter 5 Market Estimates and Forecast, by Drug Type, 2021-2034 ($ Bn)
5.1 Key trends
5.2 Monoclonal antibodies
5.3 Vaccines
5.4 Interferons alpha & beta
5.5 Interleukins
5.6 Other drug types
Chapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Bn)
6.1 Key trends
6.2 Cancer
6.3 Autoimmune diseases
6.4 Infectious diseases
6.5 Other applications
Chapter 7 Market Estimates and Forecast, by Route of Administration, 2021-2034 ($ Bn)
7.1 Key trends
7.2 Intravenous
7.3 Subcutaneous
7.4 Oral
Chapter 8 Market Estimates and Forecast, by End Use, 2021-2034 ($ Bn)
8.1 Key trends
8.2 Hospitals and clinics
8.3 Cancer research institutes
8.4 Pharmaceutical and biotechnology companies
8.5 Other End Use
Chapter 9 Market Estimates and Forecast, by Region, 2021-2034 ($ Bn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.4 Asia-Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
Chapter 10 Company Profiles

• Adaptimmune Therapeutics
• Amgen
• AstraZeneca
• Bristol Myers Squibb
• Bluebird Bio
• F. Hoffmann La Roche
• GlaxoSmithKline
• Gilead Sciences
• Johnson & Johnson
• Kite Pharma
• Merck & Co.
• Moderna
• Novartis
• Pfizer
• Sanofi

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Immunotherapy Drugs Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN05122025004107003653ID1110442016